Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda

被引:11
|
作者
Tukei, Vincent J. [1 ]
Murungi, Miriam [1 ]
Asiimwe, Alice R. [1 ]
Migisha, Daniella [1 ]
Maganda, Albert [1 ]
Bakeera-Kitaka, Sabrina [3 ]
Kalyesubula, Israel [1 ]
Musoke, Philippa [2 ,3 ]
Kekitiinwa, Adeodata [1 ]
机构
[1] Mulago Hosp, Baylor Coll Med, Bristol Myers Squibb Childrens Clin Ctr Excellenc, Kampala, Uganda
[2] Makerere Univ Johns Hopkins Univ Res Collaborat C, Kampala, Uganda
[3] Makerere Univ, Coll Hlth Sci, Dept Pediat & Child Hlth, Kampala, Uganda
来源
BMC PEDIATRICS | 2013年 / 13卷
关键词
Infant; HIV; Antiretroviral therapy; Mortality; Malnutrition; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CHILDREN; PEDIATRIC HIV; RISK-FACTORS; MORTALITY; INITIATION; OUTCOMES; YOUNG; URBAN; ART;
D O I
10.1186/1471-2431-13-42
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Antiretroviral therapy (ART) is known to save lives. Among HIV-infected infants living in resource constrained settings, the short and long term benefits of ART are only partially known. This study was designed to determine the virologic, immunologic and clinical outcomes of antiretroviral therapy in a cohort of HIV-infected infants receiving care from an outpatient clinic in Kampala, Uganda. Methods: A prospective cohort of HIV-infected infants receiving treatment at the Baylor-Uganda clinic was analyzed. Patients were diagnosed, enrolled and followed up at the clinic. HIV viral load, CD4 cell counts and clinical progress were assessed during follow-up. Descriptive statistical analysis and logistic regression modeling to determine predictors of treatment success were conducted. Results: Of 91 HIV-infected infants enrolled into the cohort, 53 (58.2%) infants were female; 43 (47.3%) were 6 months of age or younger, and 50 (55.6%) had advanced HIV/AIDS disease (Clinical stage 3 or 4). Eighty four infants started ART and 78 (92.9%) completed 6 months of treatments. Fifty six (71.8%) infants attained virologic suppression by month-6 of ART, and at month-12 of ART, the cumulative probability of attaining viral suppression was 83.1%. None of the baseline infant factors (age, sex, WHO stage, CD4 cell percent, weight for age, or height for age z-score) predicted treatment success. There was an increase in CD4 cells from a baseline mean of 23% to 30% at month-6 of treatment (p<0.001) and by month-24 of ART, the mean CD4 percent was 36%. A total of 7 patients died while on ART and another 7 experienced adverse events that were related to treatment. Conclusion: Our results show that, even among very young patients from resource constrained settings, ART dramatically suppresses HIV replication, allows immune recovery and clinical improvement, and is safe. However, baseline characteristics do not predict recovery in this age group.
引用
下载
收藏
页数:9
相关论文
共 50 条
  • [1] Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
    Vincent J Tukei
    Miriam Murungi
    Alice R Asiimwe
    Daniella Migisha
    Albert Maganda
    Sabrina Bakeera-Kitaka
    Israel Kalyesubula
    Philippa Musoke
    Adeodata Kekitiinwa
    BMC Pediatrics, 13
  • [2] Virologic and immunologic response to highly active antiretroviral therapy
    Lisa P. Jacobson
    John P. Phair
    Traci E. Yamashita
    Current Infectious Disease Reports, 2002, 4 (1) : 88 - 96
  • [3] Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence
    Press, N
    Tyndall, MW
    Wood, E
    Hogg, RS
    Montaner, JSG
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 : S112 - S117
  • [4] Update on the virologic and immunologic response to highly active antiretroviral therapy
    Jacobson L.P.
    Phair J.P.
    Yamashita T.E.
    Current Infectious Disease Reports, 2004, 6 (4) : 325 - 332
  • [5] Virologic and immunologic response to highly active antiretroviral therapy.
    Jacobson L.P.
    Phair J.P.
    Yamashita T.E.
    Current HIV/AIDS Reports, 2004, 1 (2) : 74 - 81
  • [6] Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
    Moore, AL
    Kirk, O
    Johnson, AM
    Katlama, C
    Blaxhult, A
    Dietrich, M
    Colebunders, R
    Chiesi, A
    Lungren, JD
    Phillips, AN
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) : 452 - 461
  • [7] Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children
    Asbjornsdottir, Kristjana H.
    Hughes, James P.
    Wamalwa, Dalton
    Langat, Agnes
    Slyker, Jennifer A.
    Okinyi, Hellen M.
    Overbaugh, Julie
    Benki-Nugent, Sarah
    Tapia, Kenneth
    Maleche-Obimbo, Elizabeth
    Rowhani-Rahbar, Ali
    John-Stewart, Grace
    AIDS, 2016, 30 (18) : 2835 - 2843
  • [8] Immunologic and virologic response of HIV-2 infection to antiretroviral therapy
    Clark, NM
    Sarr, AD
    Sankalé, JL
    Kanki, PJ
    Kazanjian, P
    Winfield, R
    Markovitz, DM
    AIDS, 1998, 12 (18) : 2506 - 2507
  • [9] Antiretroviral therapy in patients with chronic HIV infection:: Clinical, virologic, and immunologic consequences
    Mata, RC
    Viciana, P
    De Alarcón, A
    López-Cortés, LF
    Gómez-Vera, J
    Trastoy, M
    Cisneros, JM
    AIDS PATIENT CARE AND STDS, 2005, 19 (09) : 550 - 562
  • [10] The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
    Haubrich, RH
    Little, SJ
    Currier, JS
    Forthal, DN
    Kemper, CA
    Beall, GN
    Johnson, D
    Dubé, MP
    Hwang, JY
    McCutchan, JA
    AIDS, 1999, 13 (09) : 1099 - 1107